Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06305728 · ClinicalTrials.gov registry record

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

A clinical trial of Pancreatic Cyst, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
25
Enrollment target
8
Study locations

NCT06305728: Recruiting study of Pancreatic Cyst, sponsored by Memorial Sloan Kettering Cancer Center.

NCT06305728 is a study of Pancreatic Cyst that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants, below the 549-participant average among 18 other Pancreatic Cyst trials with a reported enrollment target (95% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06305728, a study of Pancreatic Cyst, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
25 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study, researchers will look at whether a combination of the following types of imaging with blood tests can detect PDAC in pancreatic cysts: * The ImmunoPET scan (immune-positron emission tomography scan) with the imaging agent 89Zr-DFO-HuMab-5B1 * The HP MRI scan (hyperpolarized pyruvate magnetic resonance imaging scan)

Primary Outcome

Assess preliminary sensitivity and specificity if the immunoPET is able to identify the presence or absence of adenocarcinoma or high-grade dysplasia in participants who are scheduled to undergo surgical resection.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST 89Zr-DFO-HuMab-5B1 immunoPET
  • DIAGNOSTIC_TEST HP MRI
  • COMBINATION_PRODUCT Blood assay

Study Locations (8)

New York

  • Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All protocol activites) - New York
  • Weill Cornell Medical Center (Specimen Analysis Only) - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activites) - Rockville Centre

New Jersey

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2024-03-04
Est. Completion 2030-03-04
Memorial Sloan Kettering Cancer Center

1,884 total trials

What NCT06305728 shows while recruiting

NCT06305728 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 549-participant average among 18 other Pancreatic Cyst trials with a reported enrollment target (95% lower).

The record links to 1 condition, with Pancreatic Cyst appearing as the primary indexed condition, and to 3 interventions - of which 89Zr-DFO-HuMab-5B1 immunoPET is the first listed.

NCT06305728 lists 8 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT06305728 about?

NCT06305728 is a clinical study titled "Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms". The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study,...

What is the current status of trial NCT06305728?

This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2024-03-04. Estimated completion is 2030-03-04.

What conditions does trial NCT06305728 study?

This clinical trial studies the following conditions: Pancreatic Cyst.

What interventions are being tested in trial NCT06305728?

The interventions under investigation include: 89Zr-DFO-HuMab-5B1 immunoPET (DIAGNOSTIC_TEST), HP MRI (DIAGNOSTIC_TEST), Blood assay (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06305728?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06305728 being conducted?

This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cyst

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06305728's enrollment target sits among peer trials

25 17th of 18 higher than 2 of 18 other Pancreatic Cyst trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cyst trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06305728, the US trial registry maintained by the National Library of Medicine. NCT06305728 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.